Fusion Capital’s Merck MRK Stock Holding History

Fusion Capital’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$231K	Buy	1,794 +3	+0.2%	+$351	0.05%	102
2026 Q1	$215K	Buy	+1,791	New	+$207K	0.06%	97

Other funds holding MRK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fusion Capital's MRK Position: Q2 2026 in Review

Fusion Capital increased its Merck (MRK) stake by 0.17% in Q2 2026, buying an estimated $351 and bringing the position to 1,794 shares worth $231K. The position accounts for 0.05% of the portfolio, ranked #102.

Fusion Capital first reported a position in MRK in Q1 2026 and has held it in 2 quarters since. 3,818 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

Fusion Capital held 1,794 shares of Merck worth $231K as of Q2 2026.
Fusion Capital bought 3 Merck shares in Q2 2026, an estimated $351.
Merck made up 0.05% of Fusion Capital's portfolio in Q2 2026, its #102 holding.
Fusion Capital first reported a position in Merck in Q1 2026 and has held it in 2 quarters since.
3,818 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Fusion Capital's 13F filing for Q2 2026, filed 5 Aug 2026.